| pubmed-article:15533993 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15533993 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:15533993 | lifeskim:mentions | umls-concept:C0001792 | lld:lifeskim |
| pubmed-article:15533993 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:15533993 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:15533993 | lifeskim:mentions | umls-concept:C0013415 | lld:lifeskim |
| pubmed-article:15533993 | lifeskim:mentions | umls-concept:C0078569 | lld:lifeskim |
| pubmed-article:15533993 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:15533993 | pubmed:dateCreated | 2004-11-9 | lld:pubmed |
| pubmed-article:15533993 | pubmed:abstractText | Treatment response and side effects of venlafaxine were evaluated in an open-label trial of elderly outpatients with dysthymic disorder (DD). Patients received flexible dose (up to 300 mg/d) venlafaxine (Effexor XR) for 12 weeks. Of 23 study patients, 18 completed the trial. Fourteen (60.9%) were responders in intent-to-treat analyses with the last observation carried forward, and 77.8% were responders in completer analyses. Nearly half the sample (47.8%) met criteria for remission. In the intent-to-treat sample, increased severity of depression at baseline was associated with superior response, and the presence of cardiovascular disease was associated with poorer response. Venlafaxine open-label treatment was associated with fairly high response rates and generally good tolerability in elderly patients with DD. These results indicate that in elderly patients with DD, placebo-controlled trials of a dual reuptake inhibitor such as venlafaxine would be needed to assess its efficacy or to compare its efficacy to that of other antidepressants. | lld:pubmed |
| pubmed-article:15533993 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15533993 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15533993 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15533993 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15533993 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15533993 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15533993 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15533993 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:15533993 | pubmed:issn | 0891-9887 | lld:pubmed |
| pubmed-article:15533993 | pubmed:author | pubmed-author:DevanandD PDP | lld:pubmed |
| pubmed-article:15533993 | pubmed:author | pubmed-author:NoblerMitchel... | lld:pubmed |
| pubmed-article:15533993 | pubmed:author | pubmed-author:SackeimHarold... | lld:pubmed |
| pubmed-article:15533993 | pubmed:author | pubmed-author:RooseSteven... | lld:pubmed |
| pubmed-article:15533993 | pubmed:author | pubmed-author:FitzsimonsLin... | lld:pubmed |
| pubmed-article:15533993 | pubmed:author | pubmed-author:TurretNancyN | lld:pubmed |
| pubmed-article:15533993 | pubmed:author | pubmed-author:JuszczakNicol... | lld:pubmed |
| pubmed-article:15533993 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15533993 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:15533993 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15533993 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15533993 | pubmed:pagination | 219-24 | lld:pubmed |
| pubmed-article:15533993 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15533993 | pubmed:meshHeading | pubmed-meshheading:15533993... | lld:pubmed |
| pubmed-article:15533993 | pubmed:meshHeading | pubmed-meshheading:15533993... | lld:pubmed |
| pubmed-article:15533993 | pubmed:meshHeading | pubmed-meshheading:15533993... | lld:pubmed |
| pubmed-article:15533993 | pubmed:meshHeading | pubmed-meshheading:15533993... | lld:pubmed |
| pubmed-article:15533993 | pubmed:meshHeading | pubmed-meshheading:15533993... | lld:pubmed |
| pubmed-article:15533993 | pubmed:meshHeading | pubmed-meshheading:15533993... | lld:pubmed |
| pubmed-article:15533993 | pubmed:meshHeading | pubmed-meshheading:15533993... | lld:pubmed |
| pubmed-article:15533993 | pubmed:meshHeading | pubmed-meshheading:15533993... | lld:pubmed |
| pubmed-article:15533993 | pubmed:meshHeading | pubmed-meshheading:15533993... | lld:pubmed |
| pubmed-article:15533993 | pubmed:meshHeading | pubmed-meshheading:15533993... | lld:pubmed |
| pubmed-article:15533993 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15533993 | pubmed:articleTitle | An open treatment trial of venlafaxine for elderly patients with dysthymic disorder. | lld:pubmed |
| pubmed-article:15533993 | pubmed:affiliation | Late Life Depression Clinic and the Department of Biological Psychiatry, New York State Psychiatric Institute, 1051 Riverside Drive, Unit 126, New York, NY 10032, USA. dpd3@columbia.edu | lld:pubmed |
| pubmed-article:15533993 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15533993 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:15533993 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
